Form 4: Janux Therapeutics Director Alana McNulty Receives Significant Equity Grants

Janux Therapeutics, Inc. Director Alana B. McNulty was granted 3,750 restricted stock units and options to purchase 11,667 shares of common stock on June 11, 2025, as part of her compensation.

Summary

• Alana B. McNulty, a Director of Janux Therapeutics, Inc. (JANX), was granted equity awards on June 11, 2025.
• She received 3,750 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of the Issuer's common stock.
• These RSUs will vest on the earlier of June 11, 2026, or the date of the next annual meeting of the Issuer's stockholders, subject to her continuous service.
• She was also granted stock options to purchase 11,667 shares of common stock at an exercise price of $25.46 per share.
• The shares subject to these options will vest in equal monthly installments over 12 months following June 11, 2025, and will be fully vested by the date of the next annual meeting, subject to continuous service.
• Following these transactions, Ms. McNulty beneficially owns 6,250 shares of common stock directly and 11,667 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine equity grant to a director, which is a positive step for aligning management interests with shareholders, but it does not contain information that would significantly alter the company's financial outlook or market perception beyond this standard compensation practice.

Positives

• The grant of equity awards (RSUs and stock options) to Director Alana B. McNulty aligns her interests with those of the company's shareholders.
• Equity compensation is a standard practice to incentivize long-term commitment and performance from directors.

Future Outlook

The document details future vesting schedules for the granted equity awards, with RSUs vesting by June 11, 2026, or the next annual meeting, and stock options vesting monthly over 12 months from June 11, 2025, fully vested by the next annual meeting, all contingent on continuous service.

Industry Context

This Form 4 filing reflects a routine equity compensation grant to a director, a common practice across industries, particularly in biotechnology, to attract and retain talent and align leadership incentives with shareholder value creation. Such grants are standard components of a director's overall compensation package.

Comparison to Industry Standards

• The equity grants to Director Alana B. McNulty are consistent with typical compensation structures for non-employee directors in the biotechnology sector.
• While specific comparable companies or projects are not detailed in this filing, equity awards like RSUs and stock options are widely used by companies of similar size and stage to Janux Therapeutics to incentivize long-term commitment and performance.
• The vesting schedules are also standard, promoting retention over a defined period.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially fostering decisions that enhance long-term shareholder value.
• Management/Board: Reinforces the compensation structure for board members, potentially aiding in director retention and motivation.

Next Steps

• Vesting of 3,750 Restricted Stock Units (RSUs) on the earlier of June 11, 2026, or the date of the next annual meeting of stockholders.
• Monthly vesting of stock options for 11,667 shares over 12 months following June 11, 2025, with full vesting by the next annual meeting.

Key Dates

Keywords

Janux Therapeutics, JANX, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Alana B. McNulty, Corporate Governance